Lung Cancer

Immunotherapy after chemotherapy and radiation provides a survival benefit for patients with unresectable, stage III non-small cell lung cancer (NSCLC), according to real-world data published in JAMA Network Open .  Researchers noted that the PACIFIC trial (ClinicalTrials.gov Identifier: NCT02125461) established a role for the use of immunotherapy after chemoradiation in this patient population.  However, the general population of patients with unresectable, stage III NSCLC in the United States may differ from patients enrolled in the PACIFIC trial.  Continue Reading To assess real-world outcomes of immunotherapy after chemoradiation, the researchers analyzed data from the National Cancer Database.  The analysis included 23,811 patients who were newly diagnosed with unresectable, stage III NSCLC between 2015 and 2017. The median age at baseline was 66 (range, 59-72) years, 43.9% of patients were women, and 84.

[unable to retrieve full-text content] Cost-effectiveness of Post-Mastectomy Radiotherapy (PMRT) for breast cancer in India: An economic modelling study    The Lancet

Share on Pinterest Smoking is still the most common cause of lung cancer, but an increasing percentage of lung cancer patients who have never smoked and are under age 40 are being diagnosed with the disease. Renata Angerami/Getty Images The American Lung Association has released its annual Lung Health Barometer survey. Overall, the pace of lung cancer deaths is down, but it remains stubbornly high. While smoking remains the number one cause of lung cancer, a growing number of non-smokers under age 40 are being diagnosed. Emily Daniels, who lives with her husband and their young son in Golden, CO, was 32 years old, and in the 33rd week of her pregnancy, she began feeling tightness in her chest. She wisely had it checked out, and a CT scan found two blood clots in her lungs. The scan also discovered a mass, which a biopsy confirmed was stage IV lung cancer. Daniels, who has never smoked, was shocked to hear the diagnosis. Her doctors aren't sure how she got cancer. But they told her

Unsurprisingly, the U.S. News & World Report 2022-2023 list of America's Best Hospitals is filled with mesothelioma cancer centers . Mayo Clinic again is ranked as the best hospital in the United States. The facility is considered one of the best mesothelioma hospitals in the world for patients, particularly due to the large number of clinical trials. This list is intended to assist patients in finding high-quality care for their health issues. Whether this is cancer or another serious illness, people should put their trust in the best medical facilities and doctors available. These hospitals are led by highly qualified doctors, surgeons and oncologists for mesothelioma , lung cancer and ovarian cancer, all types of cancer caused by asbestos. So people with asbestos cancer, no matter what type, can feel confident visiting any of the mesothelioma hospitals included in the Best Hospitals rankings. Since mesothelioma is one of the rarest types of cancer, finding

Lung cancer can be deadly and difficult to treat. Research into the development of new treatments is ongoing. Immunotherapy, or assisting the body's immune system in fighting cancer, is one treatment that is sometimes effective for people who have lung cancer. Results from a recent study found that combining a type of immunotherapy with a KRAS inhibitor may be effective in treating lung cancer but only in a specific subgroup of tumors. Researchers have been working on developing treatment options to help increase the survival rates among people with lung cancer. Now, a recent study published in the journal Science Advances reports that combining a specific KRAS inhibitor medication with immunotherapy may be an effective treatment for some people with lung cancer. Lung cancer has a high mortality rate. Worldwide, lung cancer is the leading cause of cancer death . The type of lung cancer will impact treatment options and strategies. One of the most common lung cancer types is non-s

Specialty pharmacists play critical role in supporting treatment adherence. Although melanoma accounts for approximately 1% of skin cancer diagnoses, it is responsible for a large portion of lives lost to the disease, with approximately 8000 deaths predicted to occur in the United States in 2022. 1 A main reason for the high morbidity rate is that melanoma is much more likely to metastasize than other skin cancers. Despite the high morbidity rate of melanoma, the disease accounts for only 5.6% of all new cancer cases in the United States, with the incidence of melanoma increasing steadily for several decades. 1 Based on this statistic, the American Cancer Society estimates that 100,000 new melanoma diagnoses will occur in the United States in 2022. 2 Current Treatments The exact cause of malignant melanoma is unknown, but it is believed to be linked to excessive UV exposure from the sun and tanning beds. As such, most melanomas are highly preventable through limited UV exposure, use

Lung cancer is the third most common cancer in the UK, but the condition's symptoms can sometimes be mistaken for a cough or cold. With around 40,000 cases of lung cancer being diagnosed every year, the condition can be fatal which is why it is important to be aware of its warning signs. In most cases it is easier to treat the sooner it is caught, according to Cancer Research UK. It comes as a woman has told how she is lucky to be alive after she was diagnosed with the deadly form of cancer. Karen McCarthy, 60, went to see her GP after suffering from what she believed was a bad chest infection for two weeks. Karen then discovered that she had lung cancer, and had to receive surgery in which part of her lung was removed as it had a "small, non-aggressive tumour". She thankfully recovered and now urges people to speak to their GP if they are experiencing possible symptoms. NHS bosses are also urging people with certain symptoms to seek lifesaving checks as part of

Monday, Aug 1, 2022 Genentech's Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancer Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to just minutes, compared with up to an hour for IV infusion Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency South San Francisco, CA -- August 1, 2022 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),   today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq ® (atezolizumab) met its co-primar

[unable to retrieve full-text content] Ask Dr. Scott: September is Prostate Cancer Awareness Month    Fairfield Daily Republic

Abstract Bee venom (B.V.) is a toxin produced naturally by honey bees with several toxic and therapeutic efficacies. It is used in the treatment of different cancer kinds like renal, hepatic, and prostate cancer. Due to its protein nature, it is degraded in the upper gastrointestinal tract. Colon-targeted drug delivery systems represent a useful tool to protect B.V. from degradation and can be administered orally instead of I.V. infusion and traditional bee stinging. In the present study, B.V. loaded enteric-coated cross-linked microspheres were prepared by emulsion cross-linking method. Percentage yield, entrapment efficiency %, swelling degree, and in-vitro release are evaluated for prepared microspheres. Free B.V., optimized microspheres formula (F3), and doxorubicin cytotoxic effects were tested by MTT assay. Results concluded that free B.V. was more effective against the growth of human prostate adenocarcinoma (PC3) cells followed by optimized microspheres than doxorubicin. But bo